Protein gene product 9.5 (PGP9.5) expression in benign cutaneous mesenchymal, histiocytic, and melanocytic lesions: comparison with cellular neurothekeoma
Protein gene product 9.5 (PGP9.5) expression in benign cutaneous mesenchymal, histiocytic, and melanocytic lesions: comparison with cellular neurothekeoma
复制标题
DOI：
10.1016/j.pathol.2016.09.061
复制
发表时间：
2017-01-01
期刊：
影响因子：
4.5
通讯作者：
Chan, May P.
中科院分区：
文献类型：
--
作者：
Wang, Grace Y.;Nazarian, Rosalynn M.;Chan, May P.
细胞性神经上皮瘤（CNTK）经常进入良性皮肤细胞增殖的鉴别诊断。诊断通常依赖于免疫组织化学，包括使用蛋白基因产物9.5（PGP9.5）。先前的研究表明，PGP9.5在各种软组织肿瘤中表达。我们探讨了这种抗体在区分CNTK与其他良性皮肤病变的效用。一组CNTK（n = 7）和神经（n = 28）、纤维组织细胞（n = 23）、成纤维细胞（n = 25）、组织细胞（n = 18）、成肌纤维细胞（n = 7）、平滑肌（n = 14）和黑色素细胞（n = 12）分化的良性皮肤病变用PGP 9.5进行免疫染色。通过H评分对染色进行分级，并与CNTK进行比较。CNTK的H评分显著高于纤维组织细胞（p = 0.0001）、组织细胞（p = 0.0016）、肌纤维母细胞（p = 0.0003）、平滑肌（p < 0.0001）和黑素细胞（p = 0.0004）组，丛状纤维组织细胞肿瘤、黄色瘤和黄色肉芽肿除外。CNTK与成纤维细胞和神经病变相比，除神经纤维瘤和神经束膜瘤外，无显著差异。总之，PGP9.5有助于区分CNTK与大多数良性皮肤纤维组织细胞、组织细胞、肌纤维母细胞、平滑肌和黑色素细胞病变。除了CNTK和神经病变外，PGP9.5也在良性成纤维细胞病变中表达，因此这些病变的区分不应基于PGP9.5阳性。
Cellular neurothekeoma (CNTK) frequently enters the differential diagnosis of a benign dermal cellular proliferation. Diagnosis often relies on immunohistochemistry including the use of protein gene product 9.5 (PGP9.5). A previous study demonstrated PGP9.5 expression across a wide variety of soft tissue neoplasms. We explored the utility of this antibody in distinguishing CNTK from other benign dermal-based lesions. A cohort of CNTK (n = 7) and benign cutaneous lesions of neural (n = 28), fibrohistiocytic (n = 23), fibroblastic (n = 25), histiocytic (n = 18), myofibroblastic (n = 7), smooth muscle (n = 14), and melanocytic (n = 12) differentiations were immunostained with PGP9.5. Staining was graded by H-score and compared with CNTK. A significantly higher H-score was found in CNTK compared with the fibrohistiocytic (p = 0.0001), histiocytic (p = 0.0016), myofibroblastic (p = 0.0003), smooth muscle (p < 0.0001), and melanocytic (p = 0.0004) groups, with the exceptions of plexiform fibrohistiocytic tumour, xanthoma, and xanthogranuloma. No significant difference was found when comparing CNTK with fibroblastic and neural lesions, with the exceptions of neurofibroma and perineurioma. In conclusion, PGP9.5 is helpful in distinguishing CNTK from most benign cutaneous fibrohistiocytic, histiocytic, myofibroblastic, smooth muscle, and melanocytic lesions. In addition to CNTK and neural lesions, PGP9.5 is also expressed in benign fibroblastic lesions, and therefore distinction of these lesions should not be based on PGP9.5 positivity.